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PODIUM SESSION I: RESEARCH ON DATABASE METHODS
DB1
DEVELOPMENT AND VALIDATION OF A MODEL TO PREDICT 
VIROLOGIC FAILURE USING ADMINISTRATIVE CLAIMS
Juday T1, Jing Y1, Chang E2, Broder M2
1Bristol-Myers Squibb, Plainsboro, NJ, USA, 2Partnership for Health Analytic Research, LLC, 
Beverly Hills, CA, USA
OBJECTIVES: When studying HIV infection, administrative claims databases can 
provide information on treatment and cost for large numbers of patients but most do 
not contain laboratory test results, making it impossible to know when a change in 
antiretroviral treatment (ART) was due to virologic failure. Our objective was to 
develop and validate a model for identifying patients in a claims database who 
switched ART due to virologic failure. METHODS: We identiﬁed three databases of 
adult HIV-positive patients who switched ART regimens between January 1, 2003 
and March 31, 2008. The HIV Insight clinical registry was used to develop a logistic 
regression model incorporating demographics, regimen characteristics, and other inde-
pendent variables to estimate the odds of virologic failure. Next, the subset of the 
Ingenix i3 LabRx health insurance claims database with HIV viral load test results 
(claims/lab database) was used to validate the model. The model was then used to 
estimate the proportion of patients with virologic failure in the full Ingenix i3 LabRx 
claims database (claims database). RESULTS: There were 1,691 patients with ART 
switches in HIV Insight; 1,073 in the claims/lab database, and 3,954 in the claims 
database. The base model (main effects only) had good discriminatory ability (c = 
0.875); but poor overall model ﬁt (Hosmer Lemeshow test, p < 0.001). Adding three 
signiﬁcant two-way interaction terms improved ﬁt (p = 0.8692) and discriminatory 
ability (c = 0.885). When the ﬁnal model was applied to the claims/lab database, it 
predicted 18.9% of patients would have virologic failure; the actual proportion was 
18.6%. CONCLUSIONS: We developed and validated a model that could be used in 
administrative claims to predict the proportion of ART switches due to virologic 
failure. Health plans may use this model to identify treatments with rising rates of 
virologic failure and to examine costs related to such failure.
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ADMINISTRATIVE HEALTH CARE CLAIMS
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OBJECTIVES: Mode of survey administration is an important determinant of the 
validity/accuracy of self-reported, health care utilization (HCRU). While Internet-
based surveys are becoming more common, little is known about agreement between 
administrative claims data and Internet-based survey self- and proxy-reported HCRU. 
This analysis evaluated the level of agreement of self- and proxy-reported HCRU as 
recorded through an Internet-based survey as compared to administrative claims-based 
HCRU data from three large self-insured U.S. employers. METHODS: Monthly 
Internet-based surveys of employees (n = 2,298) in the Child and Household Inﬂuenza-
Illness and Employee Function Study were captured 11/07–5/08. The survey captured 
data on the presence and number of visits to hospitals, emergency departments, urgent 
care centers and ofﬁce visits for employees’ care and for household member (HHM) 
care (n = 6,884). Administrative claims from the Marketscan® Databases were 
assessed during the same time period and evaluated relative to the survey-based HCRU 
metrics. Only data for individuals with employer-sponsored health care coverage and 
who could be linked to the claims data using via direct matching was included (n = 
5,718, 62%). The Kappa (κ) statistic was used to evaluate visit concordance and 
correlation statistics were used to describe frequency consistency. RESULTS: There 
was moderate to substantial visit presence and frequency agreement between survey-
based and claims-based HCRU for all service categories. Percent agreement for pres-
ence of a particular service ranged from 99.2% (inpatient stay, κ = 0.71) to 76.4% 
(outpatient visits, κ = 0.52). The correlation in the survey-based and claims-based visit 
frequency for inpatient, emergency department, urgent care center and outpatient visits 
was 0.59, 0.66, 0.42 and 0.61 respectively (all p < 0.001). Visit presence and frequency 
agreement was similar for self- and proxy-reported HCRU. CONCLUSIONS: Relative 
to previously published HCRU metrics elicited from paper and telephony survey 
methods, this study’s agreement values suggest that Internet-based surveys are an 
effective method to collect self- and proxy-reported HCRU.
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MUCH ADO ABOUT THE LACK OF SOCIO-ECONOMIC COVARIATES IN 
ADMINISTRATIVE CLAIMS DATA
Borah B
Mayo Clinic, Rochester, MN, USA
OBJECTIVES: Administrative claims data from managed care plans are often used to 
assess health care utilization and cost. However, a major criticism against the use of 
claims data is that they often lack socio-economic-status (SES) information including 
race, years of education, marital status and household income. Therefore, claims-based 
estimates of utilization and cost measures may be biased. Using Medical Expenditures 
Panel Survey (MEPS), this paper shows that the SES factors may not have signiﬁcant 
bearing on the predicted utilization and cost measures. METHODS: The 2007 
MEPS data were used for this study. In order to make the study sample resemble a 
typical sample from claims data from a managed care plan, MEPS patients 
aged between 18 and 65 years enrolled in a managed care plan throughout 2007 
were included in the ﬁnal sample. Overall and pharmacy costs were analyzed using 
generalized linear modeling (GLM) with gamma distribution and log link while the 
number of ofﬁce and outpatient visits were modeled using GLM with Poisson distribu-
tion and log link. Each regression was run with and without the four SES variables, 
and the resulting predicted values were compared. RESULTS: The predicted number 
of ofﬁce and outpatient visits with SES covariates in the GLM regression equation 
were 2.81(SD = 1.92) and 0.43(SD = 0.65), and without SES covariates were 2.83(SD 
= 1.91) and 0.41(SD = 0.61). Similarly, the predicted pharmacy and total health care 
cost with SES covariates were $897(SD = $1,562) and $3,990(SD = $4,697), and 
without SES covariates were $854(SD = $1,334) and $4,101(SD = $4,633). Thus, 
predicted utilization and cost measures with or without the SES variables in the cor-
responding GLM regression were not statistically different. CONCLUSIONS: Our 
results reject the hypothesis that the lack of SES covariates in claims data might result 
in biased estimates of utilization and cost. Further investigation is warranted to check 
the robustness of the model speciﬁcations for utilization and cost.
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ACCOUNTING FOR THE RELATIONSHIP BETWEEN PER DIEM COST 
AND LOS WHEN ESTIMATING HOSPITALIZATION COSTS
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OBJECTIVES: Hospitalization costs in trials are often derived using observed lengths 
of stay (LOS) and ﬁxed per diem costs obtained from supplemental data sources. This 
approach assumes per diem costs are independent of LOS, which is generally not the 
case. We sought to develop an approach that accounts for this relationship to obtain 
more accurate cost estimates. METHODS: To examine the association between peri-
operative blood pressure control and hospitalization costs for coronary artery bypass 
graft (CABG), valve surgery or combined surgeries, data from the Massachusetts Acute 
Hospital Case Mix Database for 2005–2007 were used to derive LOS-speciﬁc per 
diem costs. Regression analyses were carried out to model this relationship, allowing 
for non-linear functional forms. Costs were log-transformed to account for their 
skewed distributions. Exploratory analyses were carried out to identify suitable 
parameterizations and candidate models were compared using goodness-of-ﬁt statis-
tics. Complications occurring during hospitalization were included as predictors of 
per diem costs with a possible interaction with LOS. For illustrative purposes we 
present results for patients undergoing CABG. RESULTS: The Massachusetts database 
yielded 10,601 patients undergoing CABG. Mean ± SD LOS was 9.47 ± 5.86 days 
and per diem cost was $6,241 ± $3,019. Per diem costs varied across different com-
plications and LOS. Per diem costs were highest for patients who died in-hospital and 
those with multiple complications. Per diem costs were high for short LOS, then 
declined steadily to LOS of 14 days, and were relatively constant thereafter, showing 
a linear relationship between log per diem costs and log LOS. This model had consider-
ably better ﬁt compared to one that assumed a single per diem cost (Akaike Informa-
tion Criterion 7,825 vs. 10,440, respectively). CONCLUSIONS: Mean per diem costs 
depend highly on the LOS of the hospitalization. Accounting for the relationship 
between per diem cost and LOS yields better estimates of costs and subsequent 
inferences.
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HE1
COST-EFFECTIVENESS OF 1ST LINE CHEMOTHERAPY REGIMENS IN 
THE TREATMENT OF NON-SMALL CELL LUNG CANCER AMONG 
PATIENTS RECEIVING CARE IN THE OUTPATIENT COMMUNITY 
SETTING
Hoverman JR1, Pohl G2, Gruschkus SK3, Marciniak M2, Forsyth M3, Peltz G2
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OBJECTIVES: To evaluate the incremental cost-effectiveness of combination peme-
trexed/platinum chemotherapy relative to other common chemotherapy regimens for 
1st line treatment of non-small cell lung cancer (NSCLC). METHODS: NSCLC 
patients initiating 1st line chemotherapy (pemetrexed/platinum (P/P); carboplatin/pacli-
taxel + bevacizumab (C/P + B); or carboplatin/paclitaxel (C/P)) from July 1, 2006–June 
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